In NSCLC adenocarcinoma, the standard of care involved association of pemetrexed, platin and pembrolizumab..[7] We developed preclinical models that aimed at modeling immune-resistance: LLC1 model (a model with mutation in Kras and Tp53 gene) or lung tumor induced by the carcinogen urethane (which gives also lung tumors with mutation in Kras and Tp53 gene). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.